

Review of: "[Research Note] Semaglutide, a GLP-1 Agonist Like Ozempic, and Its Potential Role as a Preventive Anti-Cancer Agent"

Simin Li¹

¹ Southern Medical University

Potential competing interests: No potential competing interests to declare.

(1)The research work would benefit from more clearly defining its scope and purpose early on. Is it a preliminary review of the potential for semaglutide as a preventative anti-cancer agent? Or exploring optimal dosing?

(2)There is no clear description of the methodology used for the analysis and review presented. It seems to be a narrative review but this should be stated.

(3)This study focuses heavily on mechanisms and observational data but does not critically evaluate clinical trials or empirical evidence regarding dosing or efficacy. More discussion of existing studies is needed.

(4)Relatedly, the claims about preventative potential are theoretical and not yet firmly demonstrated in rigorous clinical trials. This needs to be emphasized more in the language used.

(5)The section on guiding dosage lacks specifics from clinical data and instead just describes general principles.

Reference to actual studies exploring dosing would make this section stronger.

(6)More attention could be paid to issues around long-term safety, side effects, and risks associated with chronic use of semaglutide. These concerns should be addressed.

(7)Using standardized reporting guidelines for review articles (e.g. PRISMA) would strengthen the methodology and ensure appropriate coverage of key issues.

(8)Comparisons between semaglutide and other GLP-1 agonists could better highlight any differential research findings or evidence in either preventative direction.

(9)Discussion of research limitations, gaps in the existing literature, and future studies needed would significantly improve the note.